Theralase Technologies (CVE:TLT) Trading Down 13.5% – Should You Sell?

Theralase Technologies Inc. (CVE:TLT) shares were down 13.5% during trading on Monday . The company traded as low as C$0.15 and last traded at C$0.16. Approximately 1,487,130 shares changed hands during mid-day trading, an increase of 1,348% from the average daily volume of 102,669 shares. The stock had previously closed at C$0.19.

Theralase Technologies Trading Up 3.2%

The company has a current ratio of 1.91, a quick ratio of 3.40 and a debt-to-equity ratio of 14.85. The business has a 50 day simple moving average of C$0.19 and a two-hundred day simple moving average of C$0.20. The stock has a market cap of C$41.13 million, a price-to-earnings ratio of -8.89 and a beta of -0.22.

Theralase Technologies Company Profile

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.